Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

739

Enrollment

INDUSTRY

Sponsor class

Conditions

Abscess
Wound Infection
Surgical Site Infection
Cellulitis

Interventions

DRUG: IV Dalbavancin
DRUG: Vancomycin/Linezolid

Sponsor

Durata Therapeutics Inc., an affiliate of Allergan plc